Sign In
Buy XGN
$4.54
-0.280 (-5.81%)
At Close: Jun 03, 2026
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
09:00am, Monday, 01'st Jun 2026
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, mor
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
10:56am, Thursday, 28'th May 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
01:30am, Tuesday, 12'th May 2026
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Q1 Earnings Call Highlights
01:11pm, Monday, 11'th May 2026
Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician ado
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates
10:21am, Monday, 11'th May 2026
Exagen Inc. (XGN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.2 per share a year ago.
Exagen Inc. Reports First Quarter 2026 Results
08:00am, Monday, 11'th May 2026
CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026,
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates
08:41am, Tuesday, 28'th Apr 2026
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.81 per share a year ago.
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
09:00am, Monday, 27'th Apr 2026
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026
Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of “Moderate Buy” by Analysts
02:12am, Friday, 24'th Apr 2026
Exagen Inc. (NASDAQ: XGN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, MarketBeat.com reports. One analyst has ra
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
06:50pm, Tuesday, 10'th Mar 2026
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
10:20am, Tuesday, 10'th Mar 2026
Exagen Inc. (XGN) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
08:00am, Tuesday, 10'th Mar 2026
Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWI
Exagen Inc. (NASDAQ:XGN) Receives Average Rating of “Moderate Buy” from Analysts
01:26am, Thursday, 05'th Mar 2026
Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten research firms that are presently covering the company, MarketBeat Ratings reports. One analyst
Exagen Inc. to Participate in Upcoming Investor Conferences
09:00am, Tuesday, 03'rd Mar 2026
CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor con
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
09:00am, Tuesday, 24'th Feb 2026
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 20
